Xencor, Inc. (NASDAQ:XNCR) Receives $24.50 Consensus Target Price from Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have earned an average rating of “Hold” from the ten brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $24.50.

Several brokerages have recently issued reports on XNCR. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. increased their price objective on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Zacks Research cut shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th.

Xencor Price Performance

Shares of XNCR opened at $11.97 on Friday. The firm has a 50 day simple moving average of $12.16 and a two-hundred day simple moving average of $13.35. The company has a market cap of $887.46 million, a P/E ratio of -5.23 and a beta of 0.93. Xencor has a one year low of $6.92 and a one year high of $18.69.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The company had revenue of $4.52 million for the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm’s quarterly revenue was down 86.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.66) earnings per share. On average, analysts expect that Xencor will post -3.82 earnings per share for the current fiscal year.

Insider Transactions at Xencor

In other news, SVP Celia Eckert sold 3,244 shares of the stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $11.25, for a total transaction of $36,495.00. Following the transaction, the senior vice president owned 78,685 shares of the company’s stock, valued at $885,206.25. This represents a 3.96% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP John R. Desjarlais sold 4,118 shares of the stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $46,327.50. Following the transaction, the vice president directly owned 266,333 shares in the company, valued at $2,996,246.25. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 44,020 shares of company stock valued at $499,817 in the last 90 days. 4.76% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently made changes to their positions in XNCR. BVF Inc. IL raised its holdings in shares of Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after acquiring an additional 4,393,579 shares during the last quarter. Legal & General Group Plc grew its stake in Xencor by 603.7% in the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock valued at $14,932,000 after buying an additional 1,092,095 shares in the last quarter. State Street Corp grew its stake in Xencor by 22.7% in the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock valued at $69,006,000 after buying an additional 833,423 shares in the last quarter. Jefferies Financial Group Inc. boosted its holdings in Xencor by 620.4% in the 4th quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after purchasing an additional 620,440 shares during the period. Finally, RTW Investments LP boosted its holdings in Xencor by 8.9% in the 4th quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock valued at $103,763,000 after purchasing an additional 556,407 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.